高级搜索
华蟾素配合TACE治疗肝癌的临床观察[J]. 肿瘤防治研究, 2002, 29(01): 67-68. DOI: 10.3971/j.issn.1000-8578.131
引用本文: 华蟾素配合TACE治疗肝癌的临床观察[J]. 肿瘤防治研究, 2002, 29(01): 67-68. DOI: 10.3971/j.issn.1000-8578.131
Clinical observation on cinobufotain in treating hepatocellular carcinoma after transcather arterial chemoembolization[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 67-68. DOI: 10.3971/j.issn.1000-8578.131
Citation: Clinical observation on cinobufotain in treating hepatocellular carcinoma after transcather arterial chemoembolization[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 67-68. DOI: 10.3971/j.issn.1000-8578.131

华蟾素配合TACE治疗肝癌的临床观察

Clinical observation on cinobufotain in treating hepatocellular carcinoma after transcather arterial chemoembolization

  • 摘要: 目的观察肝癌栓塞化疗联合华蟾素治疗的临床效果。方法采用已确诊的原发性肝癌236例,随机分为两组,A组采用肝癌栓塞化疗+华蟾素治疗。B组仅作栓塞化疗。 结果A组有效率、1、2、3年生存率均高于B组。自然杀伤细胞(NK)活性、T细胞亚群数值在治疗后B组明显下降,而A组较治疗前提高。结论肝动脉化疗栓塞联合华蟾素治疗肝癌,能提高疗效,改善机体免疫力,是治疗中晚期肝癌较理想的方法。

     

    Abstract: ObjectiveTo observe the clinical effect of cinobufotain on patients with liver malignancy after transcather arterial chemoembolization. Methods 236 cases of comfirmed liver cancer were randomly and equally allocated into group A and group B. The group A were given chemoembolization + cinobufotain ,The group B were only given chemoembolization. Results The effective rate、survival rate in group A are much higher than that in group B. The activity of NK,CD3,CD4,CD8,andCD4/CD8improved in group A but decreased i...

     

/

返回文章
返回